Recro eyes expansion to full-service CDMO status
![](/46/pdcnewsitem/11/36/63/HLN00CPO_Recro_990x525_scaled.jpg)
The solid oral dose specialist signs letter of intent for acquisition of a CDMO providing a full range of services
Recro Pharma, a CDMO specialising in providing complex formulation and manufacturing services for companies developing oral solid dose drug products, is looking to spread its wings by signing a non-binding letter of intent for the acquisition of a full service CDMO.
In a statement, Recro said the unnamed company in question has capabilities ranging from formulation development to commercial manufacturing for various dosage forms including oral liquids, sterile injectables, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles.
Should the acquisition complete, Recro will acquire 100% of the company for approximately $50 million.
Recro's President and Chief Executive Officer David Enloe said: “We are excited about this potential transaction and look forward to closing and sharing more details in the near term."
Currently, the CDMO has two sites in Gainesville, GA, with development and manufacturing space covering 120,000 sq. ft.
Earlier this week, the company reported strong financial results for Q2, during which time it secured new projects with Astex Pharmaceuticals and Ensysce Biosciences, as well as a new unnamed customer.
In a statement reporting these results, Enloe said the company had "continued to expand and diversify" its customer base, and "significantly" strengthened its financial position.
![Societal CDMO](https://www.cphi-online.com/c265858th_S-comp265858.jpg)
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance